-
公开(公告)号：US08697047B2
公开(公告)日：2014-04-15
申请号：US13149041
申请日：2011-05-31
Applicant: Helene Le Buannec , Daniel Zagury
Inventor： Helene Le Buannec , Daniel Zagury
CPC classification number: A61K39/385 , A61K39/0005 , A61K47/6415 , A61K47/643 , A61K47/646 , A61K2039/6075 , A61K2039/6081 , A61K2039/62 , A61K2039/622
Abstract: The invention relates to a stable immunogenic product for the induction of antibodies against one or more antigenic proteins in a subject. The invention is characterized in that it comprises proteinaceous immunogenic heterocomplexes which are formed by associations between (i) antigenic protein molecules and (ii) proteinaceous carrier molecules and in that less than 40% of the antigenic proteins (i) are linked to the proteinaceous carrier molecules (ii) by a covalent bond.
Abstract translation: 本发明涉及用于诱导受试者中一种或多种抗原蛋白的抗体的稳定的免疫原性产物。 本发明的特征在于其包含通过（i）抗原蛋白分子和（ii）蛋白质载体分子之间的缔合形成的蛋白质免疫原性异复合物，并且其中少于40％的抗原蛋白（i）与蛋白质载体连接 分子（ii）通过共价键。
-
2.发明授权High-yield method for the production of human antibodies blocking the biological activity of a human cytokine 有权用于生产阻断人细胞因子生物活性的人抗体的高产率方法公开(公告)号：US08679483B2
公开(公告)日：2014-03-25
申请号：US10572361
申请日：2004-09-15
Applicant: Bernard Bizzini , Helene Le Buanec , Daniel Zagury
Inventor： Bernard Bizzini , Helene Le Buanec , Daniel Zagury
CPC classification number: C07K16/249 , A61K2039/505 , A61K2039/55561 , A61K2039/6081 , C07K16/22 , C07K16/241 , C07K16/247 , C07K2317/21
Abstract: The invention concerns a pharmaceutical composition comprising, as the active ingredient, human natural antibodies of the IgG isotype, that neutralize the activity of a human cytokine selected from VEGF, IFNα, IL-4, TNFα and TGFβ, the said neutralizing antibodies inhibiting at least 50% of the maximum biological activity induced by an amount ranging from 0.006 ng to 0.05 ng of the said cytokine in vitro.
Abstract translation: 本发明涉及一种药物组合物，其包含作为活性成分的IgG同种型的人天然抗体，其中和选自VEGF，IFNα，IL-4，TNFα和TGFβ的人细胞因子的活性，所述中和抗体在 在体外由所述细胞因子的0.006ng至0.05ng的量诱导的最大生物活性的至少50％。
-
3.发明申请Non-immunosuppressive imunogenic or vaccine composition comprising a mutated e7 protein of the hpv-16 virus 失效包含hpv-16病毒的突变e7蛋白的非免疫抑制致免疫或疫苗组合物公开(公告)号：US20060233820A1
公开(公告)日：2006-10-19
申请号：US10512045
申请日：2003-04-04
Applicant: Daniel Zagury , Helene Le Buanec , Bernard Bizzini
Inventor： Daniel Zagury , Helene Le Buanec , Bernard Bizzini
IPC: A61K39/12
CPC classification number: C07K14/005 , A61K2039/53 , C07K2319/00 , C12N2710/20022 , C12N2740/16322
Abstract: The invention relates to an immunogenic or vaccine composition inducing an immune response towards the HPV-16 Papillomavirus native E7 protein, without simultaneously inducing an immunosuppression, said composition comprising, as the active ingredient, a non immunosuppressive mutated E7 protein, comprising the amino acid sequence consisting, from the N-terminal end to the C-terminal end, in: i. the 1-19 amino acid sequence of sequence SEQ ID No. 3; ii. an amino acid sequence possessing (a) the substitution of at least one amino acid, compared to the 20-29 corresponding amino acid sequence of sequence SEQ ID No. 3 or (b) the deletion of at least four consecutive amino acids, compared to the 20-29 corresponding amino acid sequence of sequence SEQ ID No. 3; and iii. the 30-98 amino acid sequence of sequence SEQ ID No.;
Abstract translation: 本发明涉及诱导针对HPV-16乳头瘤病毒天然E7蛋白的免疫应答的免疫原性或疫苗组合物，而不同时诱导免疫抑制，所述组合物包含作为活性成分的非免疫抑制性突变E7蛋白，其包含氨基酸序列 包括从N端到C端，在：i。 序列SEQ ID No.3的1-19氨基酸序列; ii。 氨基酸序列具有（a）至少一个氨基酸的取代，与序列SEQ ID No.3的20-29对应氨基酸序列相比，或（b）至少4个连续氨基酸的缺失，与 序列SEQ ID No.3的20-29对应氨基酸序列; 和iii。 序列SEQ ID No的30-98氨基酸序列;
-
公开(公告)号：US06878370B1
公开(公告)日：2005-04-12
申请号：US09959461
申请日：2000-04-20
Applicant: Daniel Zagury , Jean-François Zagury
Inventor： Daniel Zagury , Jean-François Zagury
IPC: A61K38/00 , A61K39/00 , A61K47/48 , A61P31/18 , C07K14/525 , C07K14/54 , C07K14/545 , C07K14/57 , A61K38/19
CPC classification number: C07K14/5412 , A61K38/00 , A61K39/00 , A61K47/646 , C07K14/525 , C07K14/5406 , C07K14/5428 , C07K14/5437 , C07K14/545 , C07K14/57
Abstract: The present invention concerns a chemically modified TNF-α, and a pharmaceutical composition and a vaccine composition containing the chemically modified TNF-α which are useful for combating overproduction of native TNF-α.
Abstract translation: 本发明涉及化学修饰的TNF-α，以及包含化学修饰的TNF-α的药物组合物和疫苗组合物，其可用于防治天然TNF-α的过量产生。
-
5.发明授权Inactive but immunogenic cytokines, pharmaceutical compositions containing same, and methods of treating homeostatic disorders associated with an overproduction of cytokines 失效非活性但免疫原性细胞因子，含有其的药物组合物，以及治疗与细胞因子过量产生相关的体内平衡紊乱的方法
公开(公告)号：US6093405A
公开(公告)日：2000-07-25
申请号：US167867
申请日：1994-06-27
Applicant: Daniel Zagury , Jean-Fran.cedilla.ois Zagury , Bernard Bizzini
Inventor： Daniel Zagury , Jean-Fran.cedilla.ois Zagury , Bernard Bizzini
IPC: A61K38/16 , A61K38/19 , A61K38/21 , A61K39/00 , A61K39/21 , A61P31/18 , A61P37/04 , C07K14/16 , C07K14/52 , C07K14/56 , C12N7/06 , A61K39/395 , A61K45/05
CPC classification number: A61K39/0005 , A61K39/12 , A61K39/21 , C07K14/005 , C07K14/52 , C07K14/56 , C12N7/00 , A61K2039/5158 , A61K2039/55522 , A61K2039/6012 , C12N2740/16034 , C12N2740/16063 , C12N2740/16122 , C12N2740/16222
Abstract: Cytokines, which are biologically inactive in humans but remain immunogenic, are used in pharmaceutical compositions to promote a neutralizing immune response against native cytokines when administered to a subject in need thereof to treat homeostatic conditions and disorders associated with an overproduction of cytokines.
Abstract translation: PCT No.PCT / FR92 / 00544 Sec。 371日期1994年6月27日第 102（e）日期1994年6月27日PCT提交1992年6月17日PCT公布。 出版物WO92 / 22577 日期1992年12月23日在人类中具有生物学活性但保持免疫原性的细胞因子用于药物组合物中，以在施用于有需要的受试者时，促进对天然细胞因子的中和免疫应答，以治疗与过量产生相关的体内平衡条件和病症 细胞因子。
-
Patent Agency Ranking
公开(公告)号：US07972603B2
公开(公告)日：2011-07-05
申请号：US10527975
申请日：2003-09-16
Applicant: Helene Le Buannec , Daniel Zagury
Inventor： Helene Le Buannec , Daniel Zagury
CPC classification number: A61K39/385 , A61K39/0005 , A61K47/6415 , A61K47/643 , A61K47/646 , A61K2039/6075 , A61K2039/6081 , A61K2039/62 , A61K2039/622
Abstract: The invention relates to a stable immunogenic product for the induction of antibodies against one or more antigenic proteins in a subject. The invention is characterised in that it comprises proteinaceous immunogenic heterocomplexes which are formed by associations between (i) antigenic protein molecules and (ii) proteinaceous carrier molecules and in that less than 40% of the antigenic proteins (i) are linked to the proteinaceous carrier molecules (ii) by a covalent bond.
Abstract translation: 本发明涉及用于诱导受试者中一种或多种抗原蛋白的抗体的稳定的免疫原性产物。 本发明的特征在于其包含通过（i）抗原蛋白分子和（ii）蛋白质载体分子之间的缔合形成的蛋白质免疫原性异复合物，并且其中少于40％的抗原蛋白（i）与蛋白质载体连接 分子（ii）通过共价键。
-
7.发明授权Use of inactive immunosuppressive and/or angiogenic immunogenic proteins, for producing secretory IgA's 有权使用无活性免疫抑制和/或血管生成免疫原性蛋白，用于产生分泌型IgA公开(公告)号：US07351554B2
公开(公告)日：2008-04-01
申请号：US11302286
申请日：2005-12-14
Applicant: Daniel Zagury
Inventor： Daniel Zagury
IPC: C12P21/06
CPC classification number: C07K16/18 , A61K9/0043 , A61K39/12 , A61K39/21 , A61K2039/505 , A61K2039/53 , A61K2039/541 , A61K2039/542 , A61K2039/543 , A61K2039/545 , A61K2039/55505 , A61K2039/55544 , A61K2039/55566 , A61K2039/585 , C07K16/1036 , C07K16/1063 , C12N2740/16034 , C12N2740/16134 , C12N2740/16334
Abstract: A method for inducing a mucosal immunity with production of secretory IgA antibodies that neutralize of block a native E7 protein originating from cancerous cells, from cells infected by a human Papillomavirus or from an immune system cell. The method includes administering to a patient in need thereof, a vaccine composition containing an active compound which is the native E7 protein, the properties of which have been inactivated by at least 70% by a physical and/or a chemical treatment, by genetic recombination or by adjuvant conditions; an inactive fragment of the immunosuppressive and/or angiogenic native E7 protein; a DNA molecule encoding the immunosuppressive and/or angiogenic native E7 protein inactivated by at least 70% by mutation; or a DNA molecule encoding an inactive fragment of the immunosuppressive and/or angiogenic native E7 protein; along with an adjuvant of mucosal immunity.
Abstract translation: 一种产生分泌型IgA抗体诱导粘膜免疫的方法，其中和阻断源自癌细胞的天然E7蛋白，来自人乳头瘤病毒感染的细胞或免疫系统细胞。 该方法包括向有需要的患者施用含有天然E7蛋白的活性化合物的疫苗组合物，其性质通过物理和/或化学处理通过遗传重组已被灭活至少70％ 或通过辅助条件; 免疫抑制和/或血管生成天然E7蛋白的无活性片段; 编码通过突变至少70％灭活的免疫抑制和/或血管生成天然E7蛋白质的DNA分子; 或编码免疫抑制和/或血管生成天然E7蛋白的无活性片段的DNA分子; 以及粘膜免疫佐剂。
-
8.发明申请公开(公告)号：US20070202102A1
公开(公告)日：2007-08-30
申请号：US10572361
申请日：2004-09-15
Applicant: Bernard Bizzini , Helene Le Buanec , Daniel Zagury
Inventor： Bernard Bizzini , Helene Le Buanec , Daniel Zagury
IPC: A61K39/395 , C07K16/24
CPC classification number: C07K16/249 , A61K2039/505 , A61K2039/55561 , A61K2039/6081 , C07K16/22 , C07K16/241 , C07K16/247 , C07K2317/21
Abstract: The invention concerns a pharmaceutical composition comprising, as the active ingredient, human natural antibodies of the IgG isotype, that neutralize the activity of a human cytokine selected from VEGF, IFNα, IL-4, TNFα and TGFβ, the said neutralizing antibodies inhibiting at least 50% of the maximum biological activity induced by an amount ranging from 0.006 ng to 0.05 ng of the said cytokine in vitro.
Abstract translation: 本发明涉及一种药物组合物，其包含作为活性成分的IgG同种型的人天然抗体，其中和选自VEGF，IFNα，IL-4，TNFα和TGFβ的人细胞因子的活性，所述中和抗体至少抑制 在体外由所述细胞因子的0.006ng至0.05ng的量诱导的最大生物活性的50％。
-
9.发明申请Use of inactive immunosuppressive and/or angiogenic immunogenic proteins, for producing secretory IgA's 有权使用无活性免疫抑制和/或血管生成免疫原性蛋白，用于产生分泌型IgA公开(公告)号：US20060153863A1
公开(公告)日：2006-07-13
申请号：US11302286
申请日：2005-12-14
Applicant: Daniel Zagury
Inventor： Daniel Zagury
IPC: A61K39/12
CPC classification number: C07K16/18 , A61K9/0043 , A61K39/12 , A61K39/21 , A61K2039/505 , A61K2039/53 , A61K2039/541 , A61K2039/542 , A61K2039/543 , A61K2039/545 , A61K2039/55505 , A61K2039/55544 , A61K2039/55566 , A61K2039/585 , C07K16/1036 , C07K16/1063 , C12N2740/16034 , C12N2740/16134 , C12N2740/16334
Abstract: A method for inducing a mucosal immunity with production of secretory IgA antibodies that neutralize of block a native E7 protein originating from cancerous cells, from cells infected by a human Papillomavirus or from an immune system cell. The method includes administering to a patient in need thereof, a vaccine composition containing an active compound which is the native E7 protein, the properties of which have been inactivated by at least 70% by a physical and/or a chemical treatment, by genetic recombination or by adjuvant conditions; an inactive fragment of the immunosuppressive and/or angiogenic native E7 protein; a DNA molecule encoding the immunosuppressive and/or angiogenic native E7 protein inactivated by at least 70% by mutation; or a DNA molecule encoding an inactive fragment of the immunosuppressive and/or angiogenic native E7 protein; along with an adjuvant of mucosal immunity.
Abstract translation: 一种产生分泌型IgA抗体诱导粘膜免疫的方法，其中和阻断源自癌细胞的天然E7蛋白，来自人乳头瘤病毒感染的细胞或免疫系统细胞。 该方法包括向有需要的患者施用含有天然E7蛋白的活性化合物的疫苗组合物，其性质通过物理和/或化学处理通过遗传重组已被灭活至少70％ 或通过辅助条件; 免疫抑制和/或血管生成天然E7蛋白的无活性片段; 编码通过突变至少70％灭活的免疫抑制和/或血管生成天然E7蛋白质的DNA分子; 或编码免疫抑制和/或血管生成天然E7蛋白的无活性片段的DNA分子; 以及粘膜免疫佐剂。
-
公开(公告)号：US20060013800A1
公开(公告)日：2006-01-19
申请号：US11135660
申请日：2005-05-24
Applicant: Helene Le Buanec , Daniel Zagury
Inventor： Helene Le Buanec , Daniel Zagury
IPC: A61K38/19 , C07K14/525
CPC classification number: A61K39/385 , A61K39/0005 , A61K47/6415 , A61K47/643 , A61K47/646 , A61K2039/6075 , A61K2039/6081 , A61K2039/62 , A61K2039/622
Abstract: A stable immunogenic product for the induction of antibodies against one or more antigenic proteins in a subject, characterized in that it comprises proteinaceous immunogenic heterocomplexes which are formed by associations between (i) antigenic protein molecules and (ii) proteinaceous carrier molecules and in that less than 40% of the antigenic proteins (i) are linked to the proteinaceous carrier molecules (ii) by a covalent bond.
Abstract translation: 用于诱导受试者中一种或多种抗原蛋白的抗体的稳定的免疫原性产物，其特征在于其包含由（i）抗原性蛋白质分子和（ii）蛋白质载体分子之间的缔合形成的蛋白质免疫原性异复合物， 超过40％的抗原蛋白质（i）通过共价键与蛋白质载体分子（ii）连接。
-
-
-
-
-
-
-
-
-
Search Results
26
records
(took 0.021 seconds)
